Studies focused on role of the immune system in disease development, and contributing genetic and environmental factors, may elicit better therapeutic approaches to small- and large-vessel vasculitis
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
Fellow’s Forum Case Report: True Vasculitis or Vasculitis Mimic?
Rheumatologists face the emerging picture of cocaine and levamisole-associated vasculopathy in clinical practice
Maintenance of Remission in ANCA-Associated Vasculitis
Relapses are common, but difficult to predict and prevent.
Case Study: 66-Year-Old Man with Visual Loss, Headache, Hematuria, Chronic Sinusitis
A 66-year-old man presented to the hospital with left-sided visual loss, headache, hematuria, and symptoms of a chronic sinusitis.
Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.
Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash
A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.